Shared care protocol – leflunomide in adults
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v2.0
Last updated: 28th July 2026
Shared care protocol – methotrexate in adults (excluding cancer)
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v2.0
Last updated: 21st July 2026
Shared care protocol – sulfasalazine in adults
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v2.0
Last updated: 9th June 2026
Budget impact of emollient bath and shower preparations
The purpose of this bulletin is to promote cost effective prescribing by highlighting the lack of evidence on the efficacy of emollient bath and shower preparations for the management of atopic eczema, in line with updated NICE guidance. It considers the potential savings that could be achieved with reduced prescribing of these products across the ICSs in the North East & Yorkshire region and Greater Manchester.
This publication was updated in April 2025 – First published in February 2023
Monthly formulary amendments – November 2024
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in November 2024.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Shared care protocol – mycophenolate mofetil & mycophenolic acid in adults (non-transplant)
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v1.1
Last updated: 10th December 2024
Shared care protocol – azathioprine and mercaptopurine for adults
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v1.2
Last updated: 26th November 2024.
Shared care protocol – ciclosporin (oral) for adults (non-transplant)
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v1.1
Last updated: 26th November 2024
Formulary assessment – Melatonin (Ceyesto) 1mg/ml oral solution
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.